Author:
Nitz Ulrike Anneliese,Mohrmann Svjetlana,Fischer Johannes,Lindemann Walter,Berdel Wolfgang E,Jackisch Christian,Werner Christoph,Ziske Carsten,Kirchner Hartmut,Metzner Bernd,Souchon Rainer,Ruffert Ute,Schütt Gerhart,Pollmanns Anke,Schmoll Hans Joachim,Middecke Constantin,Baltzer Jörg,Schrader Iris,Wiebringhaus Herrmann,Ko Yon,Rösel Siegfried,Schwenzer Thomas,Wernet Peter,Hinke Axel,Bender Hans Georg,Frick Markus
Reference31 articles.
1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005
2. Roché H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. In: Proceedings of 27th Annual Breast Cancer Symposium, 2004, San Antonio, TX, USA: abstr 27.
3. Jones SE, Savin MA, Asmar L, et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). In: Grunberg SM, ed. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, 2003, Chicago, IL, USA: abstr 59.
4. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28;Mamounas;J Clin Oncol,2005
5. Adjuvant docetaxel for node-positive breast cancer;Martin;N Engl J Med,2005
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献